BRAF and cancer: According to research related to cancers, different potential factors might play various roles in the acquired resistance and efficiency of selumetinib, such as KRAS/BRAF mutation status, abnormal ERK activity, hyperactivation of the PI3K-mTOR pathway, and upregulated scaffold protein CEMIP via a Wnt-dependent pathway 25-27.